BlackRock Inc. Takes $275.50 Million Position in Dyne Therapeutics, Inc. $DYN

Key Points

• BlackRock acquired 12.4 million Dyne Therapeutics shares worth approximately $275.5 million, giving it a 6.64% stake. Institutional investors and hedge funds collectively own 96.68% of the company.
• Analyst sentiment remains broadly positive, with an average “Moderate Buy” rating and a $34.42 price target, although one research firm downgraded the stock to “strong sell.”
• Dyne shares opened at $26.36, near their 12-month high of $27.31, while the company reported a quarterly EPS loss of $1.08—worse than the $0.75 consensus estimate. Insiders sold roughly 4.14 million shares worth $99.45 million over the past three months.

BlackRock Inc. acquired a new position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 12,404,330 shares of the company's stock, valued at approximately $275,500,000. BlackRock Inc. owned approximately 6.64% of Dyne Therapeutics at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the stock. Hilton Head Capital Partners LLC acquired a new position in shares of Dyne Therapeutics in the first quarter worth $26,000. Strs Ohio acquired a new stake in shares of Dyne Therapeutics during the fourth quarter valued at $51,000. Aster Capital Management DIFC Ltd purchased a new stake in Dyne Therapeutics during the 4th quarter worth about $84,000. Steward Partners Investment Advisory LLC increased its position in Dyne Therapeutics by 102.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company's stock worth $95,000 after purchasing an additional 2,465 shares in the last quarter. Finally, Persistent Asset Partners Ltd acquired a new position in Dyne Therapeutics in the 2nd quarter valued at about $124,000. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Jason P. Rhodes sold 2,160,516 shares of the firm's stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $25.00, for a total value of $54,012,900.00. Following the transaction, the director owned 428,946 shares in the company, valued at approximately $10,723,650. This trade represents a 83.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Erick Lucera sold 2,362 shares of Dyne Therapeutics stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $20.37, for a total transaction of $48,113.94. Following the transaction, the chief financial officer directly owned 121,563 shares in the company, valued at approximately $2,476,238.31. This trade represents a 1.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 4,139,196 shares of company stock valued at $99,449,852. Corporate insiders own 9.46% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on DYN shares. Royal Bank Of Canada raised their price target on shares of Dyne Therapeutics from $30.00 to $35.00 and gave the stock an "outperform" rating in a research note on Thursday, July 30th. HC Wainwright reissued a "buy" rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research note on Monday, August 17th. Wall Street Zen lowered shares of Dyne Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 1st. Evercore set a $33.00 target price on shares of Dyne Therapeutics in a research note on Friday, May 15th. Finally, TD Cowen started coverage on Dyne Therapeutics in a report on Friday, June 26th. They issued a "buy" rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Dyne Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $34.42.

Dyne Therapeutics Price Performance

Shares of Dyne Therapeutics stock opened at $26.36 on Thursday. Dyne Therapeutics, Inc. has a twelve month low of $11.92 and a twelve month high of $27.31. The stock has a market capitalization of $4.92 billion, a P/E ratio of -7.92 and a beta of 1.07. The company has a current ratio of 12.02, a quick ratio of 12.02 and a debt-to-equity ratio of 0.28. The business's fifty day moving average price is $24.13 and its 200 day moving average price is $19.96.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.33). As a group, research analysts anticipate that Dyne Therapeutics, Inc. will post -3.47 earnings per share for the current year.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source